HRAS and neoplasm: Importantly, KO of TNFAIP3 inhibited tumor growth promoted by both mutant H-Ras and FGFR1 activation, suggesting that TNFAIP3 may serve as a potential target for inhibiting ER- breast cancer with active mutant Ras and/or active FGFR1 signaling.